Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cobra Biologics
Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
An industry consortium will drive forward new manufacturing processes in parallel with the Oxford group’s COVID-19 vaccine clinical studies; these studies could produce Phase III efficacy results by this autumn.
- Contract Research, Toxicology Testing-CRO
- Other Names / Subsidiaries
- Cognate BioServices